In cancer, health-related quality of life (HRQoL) is a composite indicator of tumor symptoms and adverse events (AEs) from treatment that may reveal differences in patients' perceptions of tolerability that are not captured from standard AE reporting measures. In metastatic renal cell carcinoma, for example, studies of tyrosine kinase inhibitors (TKIs) in the first-line setting have demonstrated the important effect that differing AE profiles can have on patient preferences for treatments. In the COMPARZ study, patient perceptions of greater fatigue, mouth/throat soreness, and foot soreness with sunitinib versus pazopanib were consistent with physician-assessed AEs and associated with lower treatment satisfaction \[[@CR1]\]. However, in the PISCES study, significantly more patients preferred pazopanib over sunitinib (70% vs. 22%; *P* \< 0.001) despite an equal or worse incidence of AEs. Better HRQoL was commonly cited by patients as a reason for preferring pazopanib. Patient preference was consistent with physician preference (61% vs. 22%) \[[@CR2]\]. These results suggest that perceptions of HRQoL are multifaceted and subjective, and cannot be captured by incidence and severity of individual AEs---possibly because of individual variations in frequency and severity, and because of differences in patients' perceptions of the relevance of certain AEs. While physicians tend to focus on more serious AEs, these studies illustrate the importance of low-grade AEs and their perception for patients' HRQoL.

A comparison of the effects on HRQoL of an immune checkpoint programmed death-1 (PD-1) inhibitor (nivolumab) with the mechanistic target of rapamycin (mTOR) inhibitor everolimus in patients with advanced renal cell carcinoma has recently been published \[[@CR3]\]. CheckMate 025 was a robustly designed study comparing nivolumab and everolimus in a large patient population (*n* = 821) with renal cell carcinoma who had received prior antiangiogenic therapy \[[@CR4]\]. All procedures followed in the study were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients before they were included in the study. The primary endpoint of the study was overall survival; secondary endpoints included the objective response rate, progression-free survival, and safety. The minimum follow-up period was 14 months. Median overall survival was 25.0 months \[95% confidence interval (CI) 21.8--not reached\] in the nivolumab group and 19.6 months (95% CI 17.6--23.1) in the everolimus group \[hazard ratio (HR) 0.73; 98.5% CI 0.57--0.93; *P* = 0.002\]. The objective response rate was higher with nivolumab than with everolimus (25% vs. 5%; odds ratio 5.98; 95% CI 3.68--9.72; *P* \< 0.001). Median progression-free survival was 4.6 months (95% CI 3.7--5.4) in the nivolumab group and 4.4 months (95% CI 3.7--5.5) in the everolimus group (HR, 0.88; 95% CI 0.75--1.03; *P* = 0.11). The incidence of treatment-related AEs was lower in the nivolumab group (79%) compared with the everolimus group (88%) \[[@CR4]\]. HRQoL was assessed using the nine-item Functional Assessment of Cancer Therapy--Kidney Symptom Index--Disease-Related Symptoms (FKSI-DRS) questionnaire that measures symptoms predominantly related to kidney cancer (energy, pain, weight loss, bone pain, fatigue, dyspnea, cough, fevers, and hematuria) \[[@CR3]\]. The study had high HRQoL questionnaire completion rates (86--89%). Nivolumab was associated with significant improvement in HRQoL that began in week 20 and lasted the duration of the study. Compared with everolimus, the change from baseline to week 84 was statistically significant and observed in all items of the FKSI-DRS except bone pain \[[@CR4]\]. More patients had a clinically meaningful HRQoL improvement with nivolumab compared with everolimus (55% vs. 37%, respectively), and the time to onset of improvement was shorter with nivolumab \[[@CR3]\]. Although the open-label nature of the study could have induced a biased response, this seems unlikely to have been a major factor, given that the effects were long-lasting. In addition, the relationship between the clinical response and quality of life (QoL) components is complex, in part because the latter, being a patient-reported outcome (PRO), reflects subjective differences in the individual reports of changes in HRQoL.

The improvement observed with nivolumab compared with everolimus in CheckMate 025 is notable, given the efficacy and safety profile of everolimus in the treatment of renal cell carcinoma \[[@CR4]\]. Furthermore, the QoL improvement with nivolumab was linked to improvements in clinical outcomes, which suggests that the effect is associated with treatment efficacy rather than the absence of TKI-related AEs. An exploratory analysis showed a positive correlation between baseline HRQoL scores and overall survival \[[@CR3]\], and tumor responses with nivolumab tended to occur before HRQoL improvements: the median time to tumor response was 3.5 months (range 1.4--24.8), while the time to HRQoL response was 4.7 months (95% CI 3.7--7.5) \[[@CR3], [@CR4]\]. However, the magnitude of the effect suggests that patients treated with nivolumab experience greater treatment benefit than might be expected on the basis of the objective tumor response rate.

The study also found that baseline QoL has prognostic value. Conventionally, a patient's prognosis is determined through a review of clinical parameters, as exemplified by the Memorial Sloan Kettering Cancer Center prognostic criteria. These results suggest that a patient's reported QoL provides additional information that may allow a more accurate estimate of prognosis. It is noteworthy, however, that nivolumab was associated with better clinical outcomes than everolimus (except for progression-free survival), regardless of baseline HRQoL \[[@CR3]\].

The HRQoL instruments used in this study are the current mainstay for the assessment of QoL, although the therapeutic landscape has changed considerably since they were developed. The PRO version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a recently developed instrument that employs a flexible, fit-for-purpose approach to assess the frequency of, severity of, and interference from symptomatic treatment-associated toxicities \[[@CR5]\]. While the applicability and validity of newer tools such as the PRO-CTCAE are yet to be established for treatment with TKIs or immune checkpoint blockade, they may be used in future studies. Nevertheless, existing tools still capture the benefit of novel agents, as demonstrated by the CheckMate 025 QoL results.

Conclusions {#Sec1}
===========

Tolerability is an increasingly important aspect of renal cell carcinoma management, as patients are living longer due to efficacy advantages of modern treatments. HRQoL data provide an overall assessment of the patient-centered impact of treatment-related AEs, and the rapid and sustained HRQoL benefits of nivolumab reflect reduced treatment-related toxicity. This, and the higher number of patients with a clinically meaningful HRQoL response with nivolumab compared with everolimus, strengthens and supports observations of improved clinical outcomes.
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